Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074645 | 0.64 | GAA (0.34) | GAAMAPT | |
| SCHEMBL194389 | 0.62 | RAD52 (0.36) | GAAMAPT | |
| SCHEMBL4066430 | 0.62 | NPC1 (0.32) | MAPT | |
| SCHEMBL1162619 | 0.62 | — | — | |
| SCHEMBL1162665 | 0.62 | GAA (0.37) | GAAMAPT | |
| SCHEMBL290837 | 0.62 | — | — | |
| SCHEMBL1449815 | 0.60 | GAA (0.36) | GAAMAPT | |
| SCHEMBL1449794 | 0.60 | GAA (0.36) | GAAMAPT | |
| SCHEMBL18935280 | 0.60 | GAA (0.36) | GAAMAPT | |
| SCHEMBL4577839 | 0.60 | GAA (0.36) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022266458-A1 | 6-HETEROCYCLOALKYL-QUINAZOLINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | claimed |
| US-9078887-B2 | Bicyclic heteroaryl inhibitors of PDE4 | KALYPSYS, INC. (US) | 2015-07-14 | — | — | US | claimed |
| US-12036231-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-16 | — | — | US | disclosed |
| CN-114026083-B | Heterocyclic inhibitors of tyrosine kinases | 德州大学系统董事会 | 2024-07-09 | — | — | CN | disclosed |
| EP-3774802-B1 | COMPOUNDS AND METHODS FOR SELECTIVE PROTEOLYSIS OF GLUCOCORTICOID RECEPTORS | UNIV TEXAS (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240199554-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-06-20 | — | — | US | disclosed |
| WO-2024124056-A1 | NOVEL SULFOXIMINE ACTIVATORS OF SEROTONIN RECEPTORS | ENTHEOGENIX BIOSCIENCES, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-3551625-B1 | HETEROCYCLIC INHIBITORS OF MCT4 | VETTORE LLC (US) | 2024-06-12 | — | — | EP | disclosed |
| US-12006321-B2 | Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-06-11 | — | — | US | disclosed |
| US-11998606-B2 | Compounds and methods for selective proteolysis of glucocorticoid receptors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4373822-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | Theras Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-1463505-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Abbott Laboratories (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040087585-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2004-05-06 | — | — | US | disclosed |
| WO-2003101442-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| EP-1363873-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | disclosed |
| WO-2002070541-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-0382185-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | GAA 1861/4885MAPT 3336/4885 |
| US-20040087585-A1 | Peptide deformylase inhibitors | PDF, DPEP1, PEPD | GAA 1013/4885MAPT 3406/4885 |
| US-12006321-B2 | Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists | APLNR, AP3B1, AGTR1 | GAA 3898/4885MAPT 3809/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | GAA 1861/4885MAPT 3336/4885 |
| US-12036231-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | STING1, IRF3, CGAS | GAA 1021/4885MAPT 4863/4885 |
| US-20240199554-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | GAA 2476/4885MAPT 577/4885 |
| US-11998606-B2 | Compounds and methods for selective proteolysis of glucocorticoid receptors | NR3C1, NR3C2, GRK5 | GAA 1160/4885MAPT 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.